| WITH REGARD TO THE DOSE OF BoNT-A |
|
|
|
|
| NO CHANGE |
□ |
□ |
□ |
□ |
| I INCREASE THE DOSE |
□ |
□ |
□ |
□ |
| I DECREASE THE DOSE |
□ |
□ |
□ |
□ |
| WITH REGARD TO THE INJECTED MUSCLES |
|
|
|
|
| NO CHANGE |
□ |
□ |
□ |
□ |
| I INJECT NEW MUSCLES |
□ |
□ |
□ |
□ |
| WITH REGARD TO EMG |
|
|
|
|
| I CONSIDER STARTING TO USE EMG TO OPTIMIZE MUSCLE TARGETING |
□ |
□ |
□ |
□ |
| WITH REGARD TO THE BoNT-A PREPARATION |
|
|
|
|
| I CONTINUE WITH THIS PREPARATION |
□ |
□ |
□ |
□ |
| I TEMPORARILY INTERRUPT THIS PREPARATION |
□ |
□ |
□ |
□ |
| I SWITCH TO ANOTHER BoNT-A PREPARATION |
□ |
□ |
□ |
□ |
| I SWITCH TO A BoNT-B PREPARATION |
□ |
□ |
□ |
□ |
| I STOP BoNT THERAPY (WHATEVER THE SEROTYPE) |
□ |
□ |
□ |
□ |